-
1.发明授权公开(公告)号：US09061070B2
公开(公告)日：2015-06-23
申请号：US13620438
申请日：2012-09-14
申请人： Michael P. Belmares , Jonathan David Garman , Peter S. Lu , Michael W. Salter , Michael Tymianski
发明人： Michael P. Belmares , Jonathan David Garman , Peter S. Lu , Michael W. Salter , Michael Tymianski
CPC分类号： A61K47/48246 , A61K38/00 , A61K47/645 , C07K7/06 , C07K14/70571 , C07K2319/10
摘要： The invention provides methods for treating stroke and compositions for use in the same. The methods employ a chimeric peptide of an active peptide and an internalization peptide. The internalization peptide is a tat variant that promotes uptake of itself and a linked active peptide into a cell without substantial binding to N-type calcium channels. Use of the tat variant allows treating of stroke free of certain side effects associated with binding to N-type calcium channels. Tat variant peptides can also be linked to other active agent for use in treating other diseases.
摘要翻译： 本发明提供了治疗中风和组合物的方法。 该方法采用活性肽和内化肽的嵌合肽。 内化肽是一种tat变体，其促进其自身的摄取和连接的活性肽进入细胞，而不与N型钙通道基本结合。 使用tat变体允许治疗与结合N-型钙通道相关的某些副作用。 Tat变体肽也可以连接到其他活性剂以用于治疗其它疾病。
-
2.发明申请Co-Administration of An Agent Linked to an Internalization Peptide With an Anti-Inflammatory 有权与具有抗炎症的内化肽相关联的试剂的共同管理公开(公告)号：US20120252731A1
公开(公告)日：2012-10-04
申请号：US13377519
申请日：2010-06-10
CPC分类号： A61K47/64 , A61K31/275 , A61K31/277 , A61K38/08 , A61K38/10 , A61K45/06 , A61K47/645 , C07K16/1072 , C07K2319/10 , A61K2300/00
摘要： The invention provides methods of delivering pharmacologic agents linked to an internalization peptide, in which an inflammatory response inducible by the internalization peptide is inhibited by co-administration of an anti-inflammatory or by linking the internalization peptide to biotin or similar molecule. Such methods are premised in part on the results described in the examples whereby administration of a pharmacological agent linked to tat at high dosages is closely followed by an inflammatory response, which includes mast cell degranulation, histamine release and the typical sequelae of histamine release, such as redness, heat, swelling, and hypotension.
摘要翻译： 本发明提供了递送与内化肽连接的药理学试剂的方法，其中通过共同给予抗炎剂或通过将内化肽与生物素或类似分子连接来抑制内化肽诱导的炎症反应。 这些方法部分地基于实施例中描述的结果，其中以高剂量施用与tat连接的药剂紧随其后是炎性反应，其包括肥大细胞脱粒，组胺释放和组胺释放的典型后遗症，例如 作为发红，发热，肿胀和低血压。
-
公开(公告)号：US07459308B2
公开(公告)日：2008-12-02
申请号：US10663538
申请日：2003-09-15
CPC分类号： C07K14/705 , C07K16/28
摘要： The present invention relates to a cell surface molecules, designated cadherin-like asymmetry proteins (“CLASPs”). In particular, it relates to CLASP-2 polynucleotides, polypeptides, fusion proteins, and antibodies. The invention also relates to methods of modulating an immune response by interfering with CLASP function.
摘要翻译： 本发明涉及称为钙粘蛋白样不对称蛋白（“CLASP”）的细胞表面分子。 特别地，它涉及CLASP-2多核苷酸，多肽，融合蛋白和抗体。 本发明还涉及通过干扰CLASP功能来调节免疫应答的方法。
-
4.发明授权公开(公告)号：US08933013B2
公开(公告)日：2015-01-13
申请号：US13377519
申请日：2010-06-10
IPC分类号： A61K38/00 , A61K38/02 , A61K38/17 , A61K38/16 , A61K38/10 , C07K7/08 , A61K38/08 , A61K47/48 , A61K45/06 , A61K31/275
CPC分类号： A61K47/64 , A61K31/275 , A61K31/277 , A61K38/08 , A61K38/10 , A61K45/06 , A61K47/645 , C07K16/1072 , C07K2319/10 , A61K2300/00
摘要： The invention provides methods of delivering pharmacologic agents linked to an internalization peptide, in which an inflammatory response inducible by the internalization peptide is inhibited by co-administration of an anti-inflammatory or by linking the internalization peptide to biotin or similar molecule. Such methods are premised in part on the results described in the examples whereby administration of a pharmacological agent linked to tat at high dosages is closely followed by an inflammatory response, which includes mast cell degranulation, histamine release and the typical sequelae of histamine release, such as redness, heat, swelling, and hypotension.
摘要翻译： 本发明提供了递送与内化肽连接的药理学试剂的方法，其中通过共同给予抗炎剂或通过将内化肽与生物素或类似分子连接来抑制内化肽诱导的炎症反应。 这些方法部分地基于实施例中描述的结果，其中以高剂量施用与tat连接的药剂紧随其后是炎性反应，其包括肥大细胞脱粒，组胺释放和组胺释放的典型后遗症，例如 作为发红，发热，肿胀和低血压。
-
公开(公告)号：US08680137B2
公开(公告)日：2014-03-25
申请号：US12966871
申请日：2010-12-13
IPC分类号： A01N43/12 , A61K31/38 , A01N43/06 , C07D333/00 , C07D311/02
CPC分类号： A61K31/551 , A61K31/122 , A61K31/353 , A61K31/381 , A61K31/4245 , A61K31/427 , A61K31/428 , A61K31/433 , A61K31/4704 , A61K31/4709 , A61K31/4725 , A61K31/496 , C07D209/08 , C07D215/08 , C07D215/233 , C07D277/36 , C07D277/82 , C07D311/18 , C07D333/38 , C07D333/60 , C07D339/00 , C07D403/06 , C07D409/04 , C07D409/06 , C07D417/04 , C40B40/04 , G01N33/6872 , G01N2510/00
摘要： This invention relates to methods of screening for modulators of mammalian cell injury cause by TRPM7 gene and protein activity, compounds that modulate TRPM7 gene and protein activity and methods of treatment of mammalian cell injury using modulators of TRPM7 gene and protein activity.
摘要翻译： 本发明涉及使用TRPM7基因和蛋白质活性的调节剂筛选TRPM7基因和蛋白质活性引起的哺乳动物细胞损伤调节剂，调节TRPM7基因的化合物和蛋白质活性的方法以及哺乳动物细胞损伤治疗方法。
-
公开(公告)号：US07399467B2
公开(公告)日：2008-07-15
申请号：US11021949
申请日：2004-12-23
申请人： Peter S. Lu , Jonathan David Garman , Michael P. Belmares , Chamorro Somoza Diaz-Sarmiento , Johannes Schweizer
发明人： Peter S. Lu , Jonathan David Garman , Michael P. Belmares , Chamorro Somoza Diaz-Sarmiento , Johannes Schweizer
IPC分类号： A61K39/395
CPC分类号： C07K16/084 , C07K2317/33 , C07K2317/34 , C07K2317/92 , G01N33/56983 , G01N33/57411 , G01N33/5748 , G01N2333/025
摘要： The subject invention provides antibodies, including polyclonal and monoclonal antibodies, that bind to E6 proteins from at least three oncogenic strains of HPV. In general, the antibodies bind to amino acids motifs that are conserved between the E6 proteins of different HPV strains, particularly HPV strains 16 and 18. The subject antibodies may be used to detect HPV E6 protein in a sample, and, accordingly, the antibodies find use in a variety of diagnostic applications, including methods of diagnosing cancer. Kits for performing the subject methods and containing the subject antibodies are also provided.
摘要翻译： 本发明提供了结合来自至少三种致癌菌株的HPV的E6蛋白质的抗体，包括多克隆和单克隆抗体。 通常，抗体结合不同HPV株的E6蛋白之间保守的氨基酸基序，特别是HPV 16和18。本发明的抗体可用于检测样品中的HPV E6蛋白，因此，抗体 可用于各种诊断应用，包括诊断癌症的方法。 还提供了用于进行受试方法并含有目标抗体的试剂盒。
-
7.发明申请Polypeptides for Modulating Binding of Trp Channel Proteins and Trp- Associated Proteins 审中-公开用于调节Trp通道蛋白和Trp相关蛋白的结合的多肽公开(公告)号：US20080119412A1
公开(公告)日：2008-05-22
申请号：US10584831
申请日：2004-12-22
CPC分类号： C12N15/1138 , A61K38/00 , C07K14/47 , C07K14/705 , C07K2319/10 , C12N2799/022 , G01N2500/00
摘要： This invention relates to inhibitors and modulators of the binding between a transcient receptor potential (TRP) channel protein and a TRP-associated binding protein. In particular inhibitors and modulators of the binding between the TRPM7 channel protein and PDZ-domain containing TRP-associated proteins. These modulators and inhibitors are used to control Ca2+ transport through TRPM7 channel proteins and reduce damage to mammalian cells, including brain and spinal cord cells, after ischemia or traumatic injury.
摘要翻译： 本发明涉及过渡受体电位（TRP）通道蛋白和TRP相关结合蛋白之间的结合的抑制剂和调节剂。 特别是TRPM7通道蛋白和含有TRP相关蛋白的PDZ结构域之间的结合的抑制剂和调节剂。 这些调节剂和抑制剂用于通过TRPM7通道蛋白质控制Ca2 +转运，并在局部缺血或创伤性损伤后减少对哺乳动物细胞（包括脑和脊髓细胞）的损伤。
-
8.发明授权公开(公告)号：US08940699B2
公开(公告)日：2015-01-27
申请号：US13377523
申请日：2010-06-10
CPC分类号： A61K38/162 , A61K45/06 , C07K2319/10
摘要： The invention provides animal models and clinical trials for assessing agents for potential use in treating and effecting prophylaxis stroke and other neurological diseases, particularly those mediated at least in part by excitoxitity. The invention also provides preferred dosage and infusion regimes and pharmaceutical compositions for clinical application of such agents.
摘要翻译： 本发明提供动物模型和临床试验用于评估用于治疗和预防中风和其他神经系统疾病的潜在用途的药剂，特别是至少部分通过兴奋剂介导的那些。 本发明还提供优选的剂量和输注方案以及用于临床应用这种药剂的药物组合物。
-
公开(公告)号：US20130267470A1
公开(公告)日：2013-10-10
申请号：US13816663
申请日：2011-08-12
IPC分类号： A61K38/07
CPC分类号： A61K38/07 , A61K38/08 , A61K38/1709 , A61K38/1787 , A61K47/645 , C07K7/06 , C07K2319/10 , C12N9/0075 , C12Y114/13039 , G01N33/573 , G01N33/6872 , G01N2333/70571 , G01N2333/90254 , G01N2500/02
摘要： The invention provides methods of treatment or prophylaxis of damaging effects of penetrative injury to the brain or other part of the central nervous system. The methods are based in part on results in a rodent model of penetrative ballistic injury showing that an inhibitor of PDF-95 NMDAR interaction is effective in inhibiting neurological deficits resulting from such injury. The methods are useful for treating subjects having or at risk of penetrative brain injury, including subjects who have been shot in the head or at risk of such injury (e.g., military or law enforcement personnel).
摘要翻译： 本发明提供了治疗或预防对大脑或中枢神经系统其他部分的穿透性损伤的损伤作用的方法。 该方法部分基于穿透性弹道损伤啮齿动物模型的结果，表明PDF-95 NMDAR相互作用的抑制剂有效抑制由此类损伤引起的神经功能缺损。 这些方法对于治疗具有或具有渗透性脑损伤风险的受试者是有用的，包括头部受到攻击或有受伤风险的受试者（例如军事或执法人员）。
-
10.发明申请Treating Stroke and Other Diseases Without Inhibiting N-Type Calcium Channels 审中-公开治疗中风和其他疾病，不抑制N型钙通道公开(公告)号：US20130172230A1
公开(公告)日：2013-07-04
申请号：US13620438
申请日：2012-09-14
申请人： Michael P. Belmares , Jonathan David Garman , Peter S. Lu , Michael W. Salter , Michael Tymianski
发明人： Michael P. Belmares , Jonathan David Garman , Peter S. Lu , Michael W. Salter , Michael Tymianski
CPC分类号： A61K47/48246 , A61K38/00 , A61K47/645 , C07K7/06 , C07K14/70571 , C07K2319/10
摘要： The invention provides methods for treating stroke and compositions for use in the same. The methods employ a chimeric peptide of an active peptide and an internalization peptide. The internalization peptide is a tat variant that promotes uptake of itself and a linked active peptide into a cell without substantial binding to N-type calcium channels. Use of the tat variant allows treating of stroke free of certain side effects associated with binding to N-type calcium channels. Tat variant peptides can also be linked to other active agent for use in treating other diseases.
摘要翻译： 本发明提供了治疗中风和组合物的方法。 该方法采用活性肽和内化肽的嵌合肽。 内化肽是一种tat变体，其促进其自身的摄取和连接的活性肽进入细胞，而不与N型钙通道基本结合。 使用tat变体允许治疗与结合N-型钙通道相关的某些副作用。 Tat变体肽也可以连接到其他活性剂以用于治疗其它疾病。
-
-
-
-
-
-
-
-
-
搜索结果
29 条记录 (耗时 0.031 秒)
